Thursday 21 November 2019 ,
Thursday 21 November 2019 ,
Latest News
  • Don’t pay heed to propaganda: PM
  • Suu Kyi to contest Rohingya genocide case
  • Goods transport strike called off
  • Rice prices keep rising
  • Amnesty calls Facebook, Google rights abusers
  • Stepping into pink ball era
  • Fire burns 20 shops in capital
14 October, 2019 00:00 00 AM

FDA approves Ibsrela (tenapanor) for the treatment of Irritable Bowel Syndrome with constipation

drugs.com
FDA approves Ibsrela (tenapanor) for the treatment of Irritable Bowel Syndrome with constipation

Ardelyx, Inc. recently announced that the U.S. Food and Drug Administration has approved Ibsrela (tenapanor), a 50 mg, twice daily oral pill for the treatment of irritable bowel syndrome with constipation (IBS-C) in adults. Ibsrela is a minimally-absorbed small molecule that acts locally in the gastrointestinal (GI) tract to inhibit the sodium-hydrogen exchanger NHE3, resulting in an increase in bowel movements and a decrease in abdominal pain for IBS-C patients.

"Ibsrela has the potential to provide IBS-C patients and their doctors with a novel mechanism and an innovative approach to managing IBS-C, a highly burdensome and difficult-to-treat condition affecting more than 11 million people in the United States," commented Mike Raab, president and chief executive officer of Ardelyx.  "This approval is an extremely important and rewarding milestone for Ardelyx, and represents the culmination of years of dedication to advancing our discoveries and medicines in an effective and rigorous manner. We look forward to establishing a commercial collaboration with a partner that has the capabilities to drive the successful launch and marketing of Ibsrela in this large and underserved IBS-C patient population."

Mr. Raab continued, "With the approval of Ibsrela for IBS-C, along with the successful completion of our AMPLIFY trial in hyperphosphatemia, we've delivered on two major corporate milestones in the last two weeks due to flawless execution by the remarkable and talented team at Ardelyx. With these milestones accomplished, and the PHREEDOM trial reading out in Q4, I have great confidence that we are well positioned to file our NDA for hyperphosphatemia next year with potential approval and launch in 2021. We are excited about this next chapter for Ardelyx as we begin the development of our playbook for launch and commercialization of tenapanor for hyperphosphatemia in chronic kidney disease patients on dialysis and are excited to begin sharing more of our vision in the coming months."

Indications and Usage

Ibsrela (tenapanor) is indicated for treatment of irritable bowel syndrome with constipation (IBS-C) in adults.

Important Safety Information

Ibsrela is contraindicated in patients less than 6 years of age; in young juvenile rats, tenapanor caused death presumed to be due to dehydration. Avoid use of Ibsrela in patients 6 years to less than 12 years of age.  The safety and effectiveness of Ibsrela have not been established in pediatric patients less than 18 years of age.

Contraindications

Ibsrela is contraindicated in pediatric patients less than 6 years of age.

Ibsrela is contraindicated in patients with known or suspected mechanical gastrointestinal obstruction

Warnings and Precautions

Risk of serious dehydration in pediatric patients

Ibsrela is contraindicated in patients below 6 years of age. The safety and effectiveness of Ibsrela in patients less than 18 years of age have not been established. In young juvenile rats (less than 1 week old; approximate human age equivalent of less than 2 years of age), decreased body weight and deaths occurred, presumed to be due to dehydration, following oral administration of tenapanor. There are no data available in older juvenile rats (human age equivalent 2 years to less than 12 years).

Avoid the use of Ibsrela in patients 6 years to less than 12 years of age. Although there are no data in older juvenile rats, given the deaths in younger rats and the lack of clinical safety and efficacy data in pediatric patients, avoid the use of Ibsrela in patients 6 years to less than 12 years of age

Diarrhea

Diarrhea was the most common adverse reaction in two randomized, double-blind, placebo-controlled trials of IBS-C. Severe diarrhea was reported in 2.5% of Ibsrela-treated patients. If severe diarrhea occurs, suspend dosing and rehydrate patient.

Adverse reactions

In the two IBS-C trials, the most common adverse reaction in Ibsrela-treated patients (incidence ≥2% and greater than in the placebo group) was diarrhea (Trial 1: 16% Ibsrela vs 4% placebo; Trial 2: 15% Ibsrela vs 2% placebo).

 

Comments

Most Viewed
Digital Edition
More story
Editor Speaks

Editor Speaks

Lungs are pair of spongy organs covered with pleura in the thoracic cavity, the right one being 625gm having 3 lobes and left one being 600gm having 2…
All the exhausted husband of my dying patient wanted was a place to rest his head

All the exhausted husband of my dying patient wanted was a place to rest his head

In the midst of contented days, their lives are ruptured when she falls seriously ill. With her local hospital stumped, she is shipped far away to one…
Everything you need to know about lung cancer

Everything you need to know about lung cancer

Lung cancer is cancer that starts in the lungs. The most common type is non-small cell lung cancer (NSCLC). NSCLC makes up about 80 to 85 percent of all…
Understanding lung cancer - the basics

Understanding lung cancer - the basics

Although lung cancer is the leading cause of cancer death in the U.S. in both men and women, it is also one of the most preventable kinds of cancer. At…
Lung cancer screening can be cost effective: study

Lung cancer screening can be cost effective: study

Dennis Thompson Lung cancer screening with CT scans can be cost-effective while saving lives, a new study suggests. But, there are two caveats to that…
Changing paradigm in management of lung cancer

Changing paradigm in management of lung cancer

Lung cancer in Asia is a major public health problem as it contributes to high morbidity and mortality. The incidence of smoking continues to rise in…
How aging affects your feet

How aging affects your feet

CATHERINE MOYER, DPM Aging takes its toll on your feet as it does with the rest of your body. Given the amount of stress we place on our feet over a lifetime,…
Severe Acute Malnutrition [SAM] among children from mothers’ perspective

Severe Acute Malnutrition [SAM] among children from mothers’ perspective

It is a known fact that malnutrition is one of the major causes for mortality and morbidity of under- five children especially in developing countries.…
2nd International Uro-Oncology Congress, 2019

2nd International Uro-Oncology Congress, 2019

2nd International Uro-Oncology Congress was held in Dhaka Club and Pan Pacific Sonargaon Hotel on 9 and 10 November respectively. It was organized by…
Int’l Conference on Lung Health concludes calling for improving lung health

Int’l Conference on Lung Health concludes calling for improving lung health

The 6th International Conference on Lung Health titled ‘PULMOCON 2019’ concluded here, with a call for taking effective steps for improving…
Male hormone may help heart failure patients

Male hormone may help heart failure patients

SALYNN BOYLES Treatment with testosterone may help heart failure patients feel better and exercise more, preliminary research shows. The finding comes…
FDA approves Talicia (omeprazole magnesium, amoxicillin and rifabutin) for the treatment of H. pylori infection in adults

FDA approves Talicia (omeprazole magnesium, amoxicillin and rifabutin) for the treatment of H. pylori infection in adults

RedHill Biopharma Ltd., a specialty biopharmaceutical company primarily focused on the development and commercialization of proprietary drugs for the…

Copyright © All right reserved.

Editor : M. Shamsur Rahman

Published by the Editor on behalf of Independent Publications Limited at Media Printers, 446/H, Tejgaon I/A, Dhaka-1215.
Editorial, News & Commercial Offices : Beximco Media Complex, 149-150 Tejgaon I/A, Dhaka-1208, Bangladesh. GPO Box No. 934, Dhaka-1000.

Editor : M. Shamsur Rahman
Published by the Editor on behalf of Independent Publications Limited at Media Printers, 446/H, Tejgaon I/A, Dhaka-1215.
Editorial, News & Commercial Offices : Beximco Media Complex, 149-150 Tejgaon I/A, Dhaka-1208, Bangladesh. GPO Box No. 934, Dhaka-1000.

Disclaimer & Privacy Policy
....................................................
About Us
....................................................
Contact Us
....................................................
Advertisement
....................................................
Subscription

Powered by : Frog Hosting